Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 326

1.

Twenty-year survivorship of a cemented mobile bearing Total Knee Arthroplasty.

Milligan DJ, O'Brien S, Doran E, Gallagher NE, Beverland DE.

Knee. 2019 Aug;26(4):933-940. doi: 10.1016/j.knee.2019.06.004. Epub 2019 Jun 29.

PMID:
31262634
2.

A bet-hedging strategy for denitrifying bacteria curtails their release of N2O.

Lycus P, Soriano-Laguna MJ, Kjos M, Richardson DJ, Gates AJ, Milligan DA, Frostegård Å, Bergaust L, Bakken LR.

Proc Natl Acad Sci U S A. 2018 Nov 13;115(46):11820-11825. doi: 10.1073/pnas.1805000115. Epub 2018 Nov 1.

3.

Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial.

Anderson RA, Remedios R, Kirkwood AA, Patrick P, Stevens L, Clifton-Hadley L, Roberts T, Hatton C, Kalakonda N, Milligan DW, McKay P, Rowntree C, Scott FM, Johnson PWM.

Lancet Oncol. 2018 Oct;19(10):1328-1337. doi: 10.1016/S1470-2045(18)30500-X. Epub 2018 Sep 13.

4.

VOLAR DISLOCATION OF THE FIFTH CARPOMETACARPAL JOINT.

Milligan DJ, Thompson NW, O'Longain D.

Ulster Med J. 2018 May;87(2):133-134. Epub 2018 May 30. No abstract available.

5.

Hip Hemi-Arthroplasty vs Total Hip Replacement for Displaced Intra-Capsular Hip Fractures: Retrospective Age and Sex Matched Cohort Study.

Dawson D, Milligan D, Callachand F, Cusick L.

Ulster Med J. 2018 Jan;87(1):17-21. Epub 2018 Jan 31.

6.

Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL.

Howard DR, Munir T, McParland L, Rawstron AC, Milligan D, Schuh A, Hockaday A, Allsup DJ, Marshall S, Duncombe AS, O'Dwyer JL, Smith AF, Longo R, Varghese A, Hillmen P.

Leukemia. 2017 Nov;31(11):2416-2425. doi: 10.1038/leu.2017.96. Epub 2017 Mar 24.

7.

Changes in management policies for extremely preterm births and neonatal outcomes from 2003 to 2012: two population-based studies in ten European regions.

Bonet M, Cuttini M, Piedvache A, Boyle EM, Jarreau PH, Kollée L, Maier RF, Milligan D, Van Reempts P, Weber T, Barros H, Gadzinowki J, Draper ES, Zeitlin J; MOSAIC and EPICE research groups.

BJOG. 2017 Sep;124(10):1595-1604. doi: 10.1111/1471-0528.14639. Epub 2017 May 5.

8.

Correction: Evidence-Based Neonatal Unit Practices and Determinants of Postnatal Corticosteroid-Use in Preterm Births below 30 Weeks GA in Europe. A Population-Based Cohort Study.

Nuytten A, Behal H, Duhamel A, Jarreau PH, Mazela J, Milligan D, Gortner L, Piedvache A, Zeitlin J, Truffert P; EPICE (Effective Perinatal Intensive Care in Europe) Research Group.

PLoS One. 2017 Feb 13;12(2):e0172408. doi: 10.1371/journal.pone.0172408. eCollection 2017.

9.

Patent Ductus Arteriosus Treatment in Very Preterm Infants: A European Population-Based Cohort Study (EPICE) on Variation and Outcomes.

Edstedt Bonamy AK, Gudmundsdottir A, Maier RF, Toome L, Zeitlin J, Bonet M, Fenton A, Hasselager AB, van Heijst A, Gortner L, Milligan D, Van Reempts P, Boyle EM, Norman M; collaborators from the EPICE Research Group.

Neonatology. 2017;111(4):367-375. doi: 10.1159/000454798. Epub 2017 Jan 26.

PMID:
28125815
10.

Evidence-Based Neonatal Unit Practices and Determinants of Postnatal Corticosteroid-Use in Preterm Births below 30 Weeks GA in Europe. A Population-Based Cohort Study.

Nuytten A, Behal H, Duhamel A, Jarreau PH, Mazela J, Milligan D, Gortner L, Piedvache A, Zeitlin J, Truffert P; EPICE (Effective Perinatal Intensive Care in Europe) Research Group.

PLoS One. 2017 Jan 23;12(1):e0170234. doi: 10.1371/journal.pone.0170234. eCollection 2017. Erratum in: PLoS One. 2017 Feb 13;12 (2):e0172408.

11.

Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidation.

Varghese AM, Howard DR, Pocock C, Rawstron AC, Follows G, McCarthy H, Dearden C, Fegan C, Milligan D, Smith AF, Gregory W, Hillmen P; NCRI CLL Sub-Group.

Br J Haematol. 2017 Feb;176(4):573-582. doi: 10.1111/bjh.14342. Epub 2016 Dec 29.

12.

An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.

Ferguson P, Hills RK, Grech A, Betteridge S, Kjeldsen L, Dennis M, Vyas P, Goldstone AH, Milligan D, Clark RE, Russell NH, Craddock C; UK NCRI AML Working Group.

Haematologica. 2016 Nov;101(11):1351-1358. Epub 2016 Aug 18.

13.

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.

Burnett AK, Russell NH, Hills RK, Kell J, Nielsen OJ, Dennis M, Cahalin P, Pocock C, Ali S, Burns S, Freeman S, Milligan D, Clark RE.

Leukemia. 2017 Feb;31(2):310-317. doi: 10.1038/leu.2016.225. Epub 2016 Sep 2.

14.

Atraumatic Pantalar Avascular Necrosis in a Patient With Alcohol Dependence.

Callachand F, Milligan D, Wilson A.

J Foot Ankle Surg. 2016 Jan-Feb;55(1):207-8. doi: 10.1053/j.jfas.2015.07.024. Epub 2015 Sep 18.

PMID:
26387059
15.

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.

Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW, Jurgutis M, Kuliczkowski K, Gheorghita E, Passamonti F, Neumann F, Patki A, Gao G, Tefferi A.

JAMA Oncol. 2015 Aug;1(5):643-51. doi: 10.1001/jamaoncol.2015.1590.

PMID:
26181658
16.

A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.

Burnett AK, Russell NH, Hills RK, Kell J, Cavenagh J, Kjeldsen L, McMullin MF, Cahalin P, Dennis M, Friis L, Thomas IF, Milligan D, Clark RE; UK NCRI AML Study Group.

Blood. 2015 Jun 18;125(25):3878-85. doi: 10.1182/blood-2015-01-623447. Epub 2015 Apr 1.

17.

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.

Dennis M, Russell N, Hills RK, Hemmaway C, Panoskaltsis N, McMullin MF, Kjeldsen L, Dignum H, Thomas IF, Clark RE, Milligan D, Burnett AK.

Blood. 2015 May 7;125(19):2923-32. doi: 10.1182/blood-2014-10-608117. Epub 2015 Mar 24.

18.

Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.

Lanasa MC, Andritsos L, Brown JR, Gabrilove J, Caligaris-Cappio F, Ghia P, Larson RA, Kipps TJ, Leblond V, Milligan DW, Janssens A, Johnson AJ, Heerema NA, Bühler A, Stilgenbauer S, Devin J, Hallek M, Byrd JC, Grever MR.

Leuk Res. 2015 May;39(5):495-500. doi: 10.1016/j.leukres.2015.02.001. Epub 2015 Feb 7.

19.

A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia.

Burnett AK, Russell N, Hills RK, Panoskaltsis N, Khwaja A, Hemmaway C, Cahalin P, Clark RE, Milligan D.

Leukemia. 2015 Jun;29(6):1312-9. doi: 10.1038/leu.2015.38. Epub 2015 Feb 13.

PMID:
25676423
20.

Primary care management of early stage chronic lymphocytic leukaemia is safe and effective.

Parry HM, Damery S, Mudondo NP, Hazlewood P, McSkeane T, Aung S, Murray J, Pratt G, Moss P, Milligan DW.

QJM. 2015 Oct;108(10):789-94. doi: 10.1093/qjmed/hcv017. Epub 2015 Jan 31.

21.

Investigation of the essentiality of glutamate racemase in Mycobacterium smegmatis.

Li Y, Mortuza R, Milligan DL, Tran SL, Strych U, Cook GM, Krause KL.

J Bacteriol. 2014 Dec;196(24):4239-44. doi: 10.1128/JB.02090-14. Epub 2014 Sep 22.

22.

Reduced intensity allogeneic stem cell transplant for treatment of blastic plasmacytoid dendritic cell neoplasm.

Lokare A, Nikolousis E, Phillips N, Rudzki Z, Lovell R, Kishore B, Milligan D, Paneesha S.

Hematol Rep. 2014 Jan 29;6(1):5119. doi: 10.4081/hr.2014.5119. eCollection 2014 Jan 29.

23.

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.

Hillmen P, Gribben JG, Follows GA, Milligan D, Sayala HA, Moreton P, Oscier DG, Dearden CE, Kennedy DB, Pettitt AR, Nathwani A, Varghese A, Cohen D, Rawstron A, Oertel S, Pocock CF.

J Clin Oncol. 2014 Apr 20;32(12):1236-41. doi: 10.1200/JCO.2013.49.6547. Epub 2014 Mar 17.

24.

Improved relapse-free survival after autologous stem cell transplantation does not translate into better quality of life in chronic lymphocytic leukemia: lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study.

de Wreede LC, Watson M, van Os M, Milligan D, van Gelder M, Michallet M, Dreger P, Dearden CE, Homewood J, Dupuis J, Leporrier M, Karas M, Corront B, Baerlocher GM, Herr W, Choquet S, Niederwieser DW, Sutton L, Kröger N, de Witte TM, Schetelig On Behalf Of The Chronic Malignancies Working Party Of The Ebmt And The Uk Medical Research Council J.

Am J Hematol. 2014 Feb;89(2):174-80. doi: 10.1002/ajh.23610.

25.

Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.

Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J, Gibson BE, Wheatley K, Milligan D.

J Clin Oncol. 2013 Sep 20;31(27):3360-8. doi: 10.1200/JCO.2012.47.4874. Epub 2013 Aug 12.

PMID:
23940227
26.

Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation.

Marsh JC, Pearce RM, Koh MB, Lim Z, Pagliuca A, Mufti GJ, Perry J, Snowden JA, Vora AJ, Wynn RT, Russell N, Gibson B, Gilleece M, Milligan D, Veys P, Samarasinghe S, McMullin M, Kirkland K, Cook G; British Society for Blood and Marrow Transplantation, Clinical Trials Committee.

Bone Marrow Transplant. 2014 Jan;49(1):42-8. doi: 10.1038/bmt.2013.115. Epub 2013 Aug 5.

PMID:
23912664
27.

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.

Burnett AK, Russell NH, Hunter AE, Milligan D, Knapper S, Wheatley K, Yin J, McMullin MF, Ali S, Bowen D, Hills RK; UK National Cancer Research Institute AML Working Group.

Blood. 2013 Aug 22;122(8):1384-94. doi: 10.1182/blood-2013-04-496596. Epub 2013 Jul 9.

28.

The effects of age and gender on the diameter of the femoral canal in patients who undergo total hip replacement.

Milligan DJ, O'Brien S, Bennett D, Hill JC, Beverland DE.

Bone Joint J. 2013 Mar;95-B(3):339-42. doi: 10.1302/0301-620X.95B3.30882.

PMID:
23450017
29.

Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission.

Burnett AK, Goldstone A, Hills RK, Milligan D, Prentice A, Yin J, Wheatley K, Hunter A, Russell N.

J Clin Oncol. 2013 Apr 1;31(10):1293-301. doi: 10.1200/JCO.2011.40.5977. Epub 2013 Feb 25.

PMID:
23439754
30.

Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant.

Nikolousis E, Robinson S, Nagra S, Brookes C, Kinsella F, Tauro S, Jeffries S, Griffiths M, Mahendra P, Cook M, Paneesha S, Lovell R, Kishore B, Chaganti S, Malladi R, Raghavan M, Moss P, Milligan D, Craddock C.

Leuk Res. 2013 May;37(5):561-5. doi: 10.1016/j.leukres.2013.01.010. Epub 2013 Feb 5.

PMID:
23395505
31.

Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study.

Medd PG, Peniket AJ, Littlewood TJ, Pearce R, Perry J, Kirkland KE, Shaw BE, Potter MN, Craddock CF, Milligan DW, Fielding AK, Marks DI, Cook G; British Society of Blood and Marrow Transplantation.

Bone Marrow Transplant. 2013 Jul;48(7):982-7. doi: 10.1038/bmt.2012.261. Epub 2013 Jan 14. Erratum in: Bone Marrow Transplant. 2013 Oct;48(10):1368.

PMID:
23318533
32.

Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial.

Burnett AK, Hills RK, Grimwade D, Jovanovic JV, Craig J, McMullin MF, Kell J, Wheatley K, Yin JA, Hunter A, Milligan D, Russell NH; United Kingdom National Cancer Research Institute Acute Myeloid Leukaemia Subgroup.

Leukemia. 2013 Apr;27(4):843-51. doi: 10.1038/leu.2012.360. Epub 2012 Dec 10.

PMID:
23222369
33.

Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia.

Oscier D, Dearden C, Eren E, Fegan C, Follows G, Hillmen P, Illidge T, Matutes E, Milligan DW, Pettitt A, Schuh A, Wimperis J; British Committee for Standards in Haematology.

Br J Haematol. 2012 Dec;159(5):541-64. doi: 10.1111/bjh.12067. Epub 2012 Oct 11. No abstract available. Erratum in: Br J Haematol. 2013 Apr;161(1):154. Erem, Efrem [corrected to Eren, Efrem]. Br J Haematol. 2013 Mar;160(6):868. Dosage error in article text.

PMID:
23057493
34.

Guidelines on obtaining consent for systemic anti-cancer therapy in adults.

Treleaven J, Gadd E, Cullis J, Favre J, McLeod A, Meller S, Milligan D, Neilson R, Quinn B, Webb A, Wimperis J.

Hematology. 2012 Sep;17(5):249-54. doi: 10.1179/1607845412Y.0000000022. Review.

PMID:
22971529
35.

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison.

Burnett AK, Hills RK, Hunter AE, Milligan D, Kell WJ, Wheatley K, Yin J, McMullin MF, Dignum H, Bowen D, Russell NH; UK National Cancer Research Institute AML Working Group.

Leukemia. 2013 Jan;27(1):75-81. doi: 10.1038/leu.2012.229. Epub 2012 Aug 14.

PMID:
22964882
36.

Risk factors for hypotension in urgently intubated burn patients.

Dennis CJ, Chung KK, Holland SR, Yoon BS, Milligan DJ, Nitzschke SL, Maani CV, Hansen JJ, Aden JK, Renz EM.

Burns. 2012 Dec;38(8):1181-5. doi: 10.1016/j.burns.2012.07.004. Epub 2012 Aug 9.

PMID:
22884966
37.

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

Burnett AK, Russell NH, Hills RK, Kell J, Freeman S, Kjeldsen L, Hunter AE, Yin J, Craddock CF, Dufva IH, Wheatley K, Milligan D.

J Clin Oncol. 2012 Nov 10;30(32):3924-31. doi: 10.1200/JCO.2012.42.2964. Epub 2012 Jul 30.

PMID:
22851554
38.

The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML.

Burnett AK, Russell NH, Culligan D, Cavanagh J, Kell J, Wheatley K, Virchis A, Hills RK, Milligan D; AML Working Group of the UK National Cancer Research Institute.

Br J Haematol. 2012 Aug;158(4):519-22. doi: 10.1111/j.1365-2141.2012.09165.x. Epub 2012 May 29.

PMID:
22639959
39.

Headspace analysis of Italian and New Zealand parmesan cheeses.

Langford VS, Reed CJ, Milligan DB, McEwan MJ, Barringer SA, Harper WJ.

J Food Sci. 2012 Jun;77(6):C719-26. doi: 10.1111/j.1750-3841.2012.02730.x. Epub 2012 May 16.

PMID:
22591108
40.

Resuscitation feedback and targeted education improves quality of pre-hospital resuscitation in Scotland.

Lyon RM, Clarke S, Milligan D, Clegg GR.

Resuscitation. 2012 Jan;83(1):70-5. doi: 10.1016/j.resuscitation.2011.07.016. Epub 2011 Jul 23.

PMID:
21787739
41.

The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome.

Burnett AK, Hills RK, Hunter A, Milligan D, Kell J, Wheatley K, Yin J, McMullin MF, Cahalin P, Craig J, Bowen D, Russell N.

Leukemia. 2011 Jul;25(7):1122-7. doi: 10.1038/leu.2011.59. Epub 2011 Apr 8.

42.

A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.

Hillmen P, Cohen DR, Cocks K, Pettitt A, Sayala HA, Rawstron AC, Kennedy DB, Fegan C, Milligan DW, Radford J, Mercieca J, Dearden C, Ezekwisili R, Smith AF, Brown J, Booth GA, Varghese AM, Pocock C; NCRI CLL Sub-Group.

Br J Haematol. 2011 Mar;152(5):570-8. doi: 10.1111/j.1365-2141.2010.08317.x. Epub 2011 Jan 14.

PMID:
21231927
43.

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, Yin JA, Hunter A, Goldstone AH, Wheatley K.

J Clin Oncol. 2011 Feb 1;29(4):369-77. doi: 10.1200/JCO.2010.31.4310. Epub 2010 Dec 20.

PMID:
21172891
44.

Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation.

Michallet M, Dreger P, Sutton L, Brand R, Richards S, van Os M, Sobh M, Choquet S, Corront B, Dearden C, Gratwohl A, Herr W, Catovsky D, Hallek M, de Witte T, Niederwieser D, Leporrier M, Milligan D; EBMT Chronic Leukemia Working Party.

Blood. 2011 Feb 3;117(5):1516-21. doi: 10.1182/blood-2010-09-308775. Epub 2010 Nov 24.

45.

Levosimendan: calcium sensitizer and inodilator.

Milligan DJ, Fields AM.

Anesthesiol Clin. 2010 Dec;28(4):753-60. doi: 10.1016/j.anclin.2010.08.003. Review.

PMID:
21074750
46.

Rate of gas phase association of hydroxyl radical and nitrogen dioxide.

Mollner AK, Valluvadasan S, Feng L, Sprague MK, Okumura M, Milligan DB, Bloss WJ, Sander SP, Martien PT, Harley RA, McCoy AB, Carter WP.

Science. 2010 Oct 29;330(6004):646-9. doi: 10.1126/science.1193030.

47.

Rates of bronchopulmonary dysplasia in very preterm neonates in Europe: results from the MOSAIC cohort.

Gortner L, Misselwitz B, Milligan D, Zeitlin J, Kollée L, Boerch K, Agostino R, Van Reempts P, Chabernaud JL, Bréart G, Papiernik E, Jarreau PH, Carrapato M, Gadzinowski J, Draper E; members of the MOSAIC Research Group.

Neonatology. 2011;99(2):112-7. doi: 10.1159/000313024. Epub 2010 Aug 23.

PMID:
20733331
48.

The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry.

Michallet M, Sobh M, Milligan D, Morisset S, Niederwieser D, Koza V, Ruutu T, Russell NH, Verdonck L, Dhedin N, Vitek A, Boogaerts M, Vindelov L, Finke J, Dubois V, van Biezen A, Brand R, de Witte T, Dreger P; Chronic Leukemia Working Party of the EBMT.

Leukemia. 2010 Oct;24(10):1725-31. doi: 10.1038/leu.2010.165. Epub 2010 Aug 12.

PMID:
20703257
49.

T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma.

Thomson KJ, Morris EC, Milligan D, Parker AN, Hunter AE, Cook G, Bloor AJ, Clark F, Kazmi M, Linch DC, Chakraverty R, Peggs KS, Mackinnon S.

J Clin Oncol. 2010 Aug 10;28(23):3695-700. doi: 10.1200/JCO.2009.26.9100. Epub 2010 Jul 6.

PMID:
20606089
50.

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.

Chakraverty R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P, Milligan D, Collin M, Crawley C, Johnson P, Clark A, Parker A, Bloor A, Pettengell R, Snowden J, Pettitt A, Clark R, Hale G, Peggs K, Thomson K, Morris E, Mackinnon S.

Blood. 2010 Oct 21;116(16):3080-8. doi: 10.1182/blood-2010-05-286856. Epub 2010 Jun 29.

Supplemental Content

Loading ...
Support Center